The number of autologous cell therapy products commercially approved or approaching launch is growing, with allogeneic therapies very close behind. CDMOs need to ensure they are designing innovative processes and flexible facilities that can accommodate both autologous and allogeneic cell therapy products for small and large patient populations. In this webinar, we explore the considerations that need to be taken during development to ensure manufacturing processes and our facilities can support the high throughput needed to supply expanding patient populations once products reach commercial.  

Join the webinar to learn:

• The varied stages of product lifecycles for autologous and allogeneic therapies
• Strategies to scale-up manufacturing for late-stage therapies
• How Manufacturing by Design (MbD) can accelerate tech transfer and commercial-scale manufacturing of cell therapies